

REMARKS

The Specification has been amended to provide information regarding the electronic submission of the Sequence Listing via EFS Web and to insert previously omitted sequence identifiers. No new matter has been added. Accordingly, entry of the Sequence Listing and the associated amendments to the specification into the above-captioned case is respectfully requested.

Claims 1-11, 13-14, and 17-23 were pending and were rejected. The remaining claims were previously withdrawn, and have been canceled by the present amendment.

Claims 1 and 17 have been amended to specify particular peptides discussed in the specification as the ‘target peptide’ and the ‘negative screening peptide’, and to identify the first amino acid residue of PTH as the ‘specific amino acid residue’ of the claims. Support for this amendment is found throughout the specification, for example in paragraphs [110] and [0131]. No new matter is added by the amendment; entry of the amendment is requested. The applicant also respectfully requests reconsideration in view of the amendment and the following remarks.

Claims 1-7, 9-10, and 17-21 were rejected as allegedly anticipated by Motte, et al., J. Immunology, vol. 138(10), 3332-38 (1987). The applicant notes that claim 8, wherein the target peptide is “PTH or a fragment thereof” was not rejected over Motte, indicating that the Examiner recognized that Motte fails to disclose peptides or antibodies related to PTH. The amendment of claims 1 and 17 directs the pending claims to PTH-based peptides and specifies that the target peptide comprises PTH(1-34). In view of the amendment, this rejection is believed to be overcome, and can be withdrawn.

Claims 1-9, 11, 13, 14, and 17-23 were rejected as allegedly anticipated by Hutchison, et al., WO 03/003986. The applicant notes that claim 10, which recites an antibody which depends on ‘one specific amino acid residue’, was not rejected over Hutchison. Claims 1 and 17, the two pending independent claims, have been amended to indicate that the ‘specific amino acid residue’ is the first amino acid of PTH. In view of the amendment, the rejection based on Hutchison is believed to be overcome, and can be withdrawn.

CONCLUSION

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejection of the claims and to pass this application to issue. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.

In the event the U.S. Patent and Trademark office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 532212000100. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: August 29, 2007

Respectfully submitted,

By: /Michael G. Smith/

Michael G. Smith

Registration No.: 44,422

MORRISON & FOERSTER LLP

12531 High Bluff Drive, Suite 100

San Diego, California 92130-2040

(858) 720-5113